
|Videos|September 21, 2022
The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM
Author(s)Ajay K. Nooka, MD, Matthew James Pianko, MD
An expert reviews data from the ongoing GMMG HD7 (German) trial investigating isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) versus VRd in the treatment of transplant-eligible newly diagnosed multiple myeloma.
Advertisement
Advertisement
Related to this article

Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
2
Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist
3
FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC
4
Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial
5



